Table 5.
Previous studies of adjuvant chemotherapy in patients with resected liver metastases from colorectal cancer
| Number of resected metastases | Median follow-up (months) | Number of patients | Randomised postoperative treatments | Median TTP/PFS (months) | Median overall survival (months) | |
|---|---|---|---|---|---|---|
| Lorenz M (1998)5 | ≤6 liver metastases | ≥18 | 108 vs 111 | HAI FU/FA vs surgery alone | 14·2 vs 13·7 (NS) | 34·5 vs 40·8 (p=0·15) |
| Kemeny N (1999)6 | Any number of liver metastases | 62·7 | 74 vs 82 | Systemic FU/FA+HAI FUDR vs systemic FU/FA | 37·4 vs 17·2 (p=0·06) | 72·2 vs 59·3 (p=0·21) |
| Kemeny M (2002)7 | 1–3 liver metastases | 51 | 30 vs 45 | HAI FUDR+systemic FU vs surgery alone | 45·7%*vs 25·2%* (p=0·04) | 63·7 vs 49·0 (p=0·60) |
| Mitry E (2006)8 | ≤4 liver or lung metastases | NR | 138 vs 140 | Systemic FU/FA vs surgery alone | 26·4 vs 18·6 (p=0·059) | 61·1 vs 46·9 (p=0·125) |
| Portier G (2006)9 | Any number of liver metastases | 87 | 86 vs 87 | Systemic FU/FA vs surgery alone | 24·4 vs 17·6 (p=0·028) | 62·1 vs 46·4 (p=0·13) |
TTP=time to progression. PFS=progression-free survival. HAI=hepatic arterial infusion. FUDR=floxuridine. FU=fluorouracil. FA=folinic acid. NS=not significant. NR=not reported.
*
4-year progression-free survival rates.